Posted by Michael Wonder on 09 Feb 2023
FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer
9 February 2023 - Today, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
In April 2021, dostarlimab-gxly received accelerated approval for adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen.
